Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance

Antimicrob Agents Chemother. 2016 May 23;60(6):3845-8. doi: 10.1128/AAC.00214-16. Print 2016 Jun.

Abstract

Eight in vitro selection experiments under brincidofovir pressure elicited the known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L and the novel exonuclease domain substitutions D413Y, E303D, and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir or 17-fold when E303G was combined with V812L. The new exonuclease domain I resistance mutations selected under brincidofovir pressure add to the single instance previously reported and show the expected patterns of cross-resistance.

MeSH terms

  • Antiviral Agents / pharmacology*
  • Cidofovir
  • Cytomegalovirus / drug effects*
  • Cytomegalovirus / genetics
  • Cytomegalovirus / growth & development
  • Cytomegalovirus / isolation & purification
  • Cytomegalovirus Infections / virology
  • Cytosine / analogs & derivatives*
  • Cytosine / pharmacology
  • DNA-Directed DNA Polymerase / genetics*
  • Drug Resistance, Viral / genetics
  • Foscarnet / pharmacology
  • Ganciclovir / pharmacology
  • Gene Expression
  • Humans
  • Microbial Sensitivity Tests
  • Mutation*
  • Organophosphonates / pharmacology*
  • Protein Domains
  • Viral Proteins / genetics*

Substances

  • Antiviral Agents
  • Organophosphonates
  • UL54 protein, Human herpesvirus 5
  • Viral Proteins
  • Foscarnet
  • brincidofovir
  • Cytosine
  • DNA-Directed DNA Polymerase
  • Cidofovir
  • Ganciclovir